The Coherent X-ray Imaging (CXI) instrument specializes in hard X-ray, invacuum, high power density experiments in all areas of science. Two main sample chambers, one containing a 100 nm focus and one a 1 mm focus, are available, each with multiple diagnostics, sample injection, pump-probe and detector capabilities. The flexibility of CXI has enabled it to host a diverse range of experiments, from biological to extreme matter.

This analysis suggests that rivaroxaban and warfarin do not differ significantly in real-world rates of composite stroke and systemic embolism and major, intracranial, or GI bleeding. Rivaroxaban, however, was associated with significantly fewer VTE events and significantly better treatment persistence compared with warfarin.

Objective:  To evaluate the efficacy and tolerability of topiramate monotherapy in adults with acute manic or mixed episodes of bipolar I disorder. Methods:  In four trials, adults hospitalized with acute mania, a diagnosis of bipolar I disorder, history of ≥1 previous manic or mixed episodes, and ≥20 Young Mania Rating Scale (YMRS) score were randomized to double‐blind treatment with topiramate (target doses: 200, 400, or 600 mg/day) or placebo; two trials included an active comparator (lithium, 1500 mg/day). The core study duration in all trials was 3 weeks; three trials also had 9‐week double‐blind extensions. The primary efficacy variable was mean change from baseline in YMRS in the core 3‐week study. Results:  Changes in YMRS score during 3 weeks were not significantly different for topiramate versus placebo (mean YMRS reductions, −5.1 to −8.4). Mean YMRS reductions in lithium‐treated groups were significantly greater (p ≤ 0.001 versus placebo and topiramate). A similar pattern was observed after 12 weeks of double‐blind treatment in studies with double‐blind extensions. Paresthesia, appetite decrease, dry mouth, and weight loss were more frequently associated with topiramate than with placebo. Conclusions:  These studies do not support the efficacy of topiramate as monotherapy in acute mania or mixed episodes in adults with bipolar I disorder. Topiramate was not associated with mood destabilization measured as mania exacerbation or treatment‐emergent depression. Lithium was confirmed as an effective therapy in this population.

No abstract